HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: A prospective multicenter study (ENDOMET)

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 11, 2013, Pages 1313-1322

  Antonsen, Sofie L ^a   Høgdall, Estrid ^b   Christensen, Ib J ^c,d   Lydolph, Magnus ^e   Tabor, Ann ^a,f   Loft Jakobsen, Annika ^a   Fagö Olsen, Carsten L ^a   Andersen, Erik S ^g   Jochumsen, Kirsten ^h   Høgdall, Claus ^a  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c FINSEN LABORATORY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e STATENS SERUM INSTITUT   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

biomarkers; CA125; endometrial cancer; Gynecologic oncology; HE4; preoperative staging; risk factors

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR INVASION;

BIOMARKERS; CA125; ENDOMETRIAL CANCER; GYNECOLOGIC ONCOLOGY; HE4; PREOPERATIVE STAGING; RISK FACTORS;

ADULT; AGED; CA-125 ANTIGEN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MYOMETRIUM; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886892919     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12235     Document Type: Article

References (41)

1. Amant F, Moerman P, Neven P, Timmerman D, Van LE, Vergote I,. Endometrial cancer. Lancet. 2005; 366: 491-505.
2. Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012; 126: 186-91.
3. Antonsen SL, Ulrich L, Høgdall C,. Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecol Oncol. 2012; 125: 124-8.
4. Leitao MM Jr, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, et al. Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol. 2008; 111: 244-8.
5. Francis JA, Weir MM, Ettler HC, Qiu F, Kwon JS,. Should preoperative pathology be used to select patients for surgical staging in endometrial cancer? Int J Gynecol Cancer. 2009; 19: 380-4.
6. Kirchhoff C, Habben I, Ivell R, Krull N,. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991; 45: 350-7.
7. Galgano MT, Hampton GM, Frierson HF Jr,. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19: 847-53.
8. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65: 2162-9.
9. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110: 196-201.
10. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011; 104: 1418-25.
11. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal. 2009; 23: 331-5.
12. Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G,. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011; 21: 1185-90.
13. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC,. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981; 68: 1331-7.
14. Niloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC Jr,. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984; 148: 1057-8.
15. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW,. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol. 1986; 155: 1097-102.
16. Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE,. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol. 1994; 84: 12-6.
17. Patsner B, Mann WJ, Cohen H, Loesch M,. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol. 1988; 158: 399-402.
18. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M,. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997; 90: 441-7.
19. Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH,. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med. 2005; 50: 585-90.
20. Bergmann JF, Beaugrand M, Labadie H, Bidart JM, Bohuon C,. CA 125 (ovarian tumour-associated antigen) in ascitic liver diseases. Clin Chim Acta. 1986; 155: 163-5.
21. Goonewardene TI, Hall MR, Rustin GJ,. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007; 8: 813-21.
22. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009; 112: 40-6.
23. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008; 108: 402-8.
24. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013; 34: 571-6.
25. Mirza M, Ulrich L,. DGCG Guideline. Retningslinier for visitation, diagnostik, behandling og kontrol af cancer corpus uteri. [Guidelines for triage, diagnosis, treatment and control of cancer corpus uteri.] Available online at: http://dgc.eu.com/fundanemt/files/DGC-EC-070409-2udgave.pdf (10.09.09) (accessed May 15, 2009).
26. Høgdall CK, Nielsen MLS, Taaning L,. Annual report 2009/2010. The Danish gynaecological cancer database. Nationwide clinical database for cancer in the ovaries, uterus and cervix. Copenhagen: Lægeforeningens forlag, 2012.
27. Creasman W,. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009; 105: 109.
28. Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T,. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol. 1998; 69: 192-6.
29. Bolstad N, Oijordsbakken M, Nustad K, Bjerner J,. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012; 33: 141-8.
30. Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012; 124: 270-5.
31. Ebina Y, Sakuragi N, Hareyama H, Todo Y, Nomura E, Takeda M, et al. Para-aortic lymph node metastasis in relation to serum CA 125 levels and nuclear grade in endometrial carcinoma. Acta Obstet Gynecol Scand. 2002; 81: 458-65.
32. Kim HS, Park CY, Lee JM, Lee JK, Cho CH, Kim SM, et al. Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study. Gynecol Oncol. 2010; 118: 283-8.
33. Hsieh CH, ChangChien CC, Lin H, Huang EY, Huang CC, Lan KC, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002; 86: 28-33.
34. Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP,. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006; 85: 1501-5.
35. Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I,. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer. 2002; 12: 372-5.
36. Scambia G, Gadducci A, Panici PB, Foti E, Ferdeghini M, Ferrandina G, et al. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol Oncol. 1994; 54: 292-7.
37. Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT,. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer. 1998; 82: 1720-5.
38. Todo Y, Sakuragi N, Nishida R, Yamada T, Ebina Y, Yamamoto R, et al. Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am J Obstet Gynecol. 2003; 188: 1265-72.
39. Benedet JL, Bender H, Jones H III, Ngan HY,., Pecorelli S,. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000; 70: 209-62.
40. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK,. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373: 125-36.
41. Chi DS, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Alektiar K, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008; 18: 269-73.